These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 6817452)

  • 1. Platelet-mediated vascular contractions: inhibition of the serotonergic component by ketanserin.
    De Clerck F; Van Nueten JM
    Thromb Res; 1982 Sep; 27(6):713-27. PubMed ID: 6817452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet-mediated vascular contractions. Inhibition by flunarizine, a calcium-entry blocker.
    De Clerck F; Van Nueten JM
    Biochem Pharmacol; 1983 Mar; 32(5):765-71. PubMed ID: 6404280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet-mediated vascular permeability in the rat: a predominant role for 5-hydroxytryptamine.
    De Clerck F; Van Gorp L; Beetens J; Reneman RS
    Thromb Res; 1985 May; 38(4):321-39. PubMed ID: 3160131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ketanserin, a selective 5-HT2 serotonergic antagonist, on the secondary recruitment of human platelets in vitro.
    De Clerck F; Xhonneux B
    Agents Actions; 1986 Mar; 17(5-6):515-26. PubMed ID: 2939698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist.
    de Clerck F; David JL; Janssen PA
    Agents Actions; 1982 Jul; 12(3):388-97. PubMed ID: 6215842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Hydroxytryptamine can mediate endothelium-dependent relaxation of coronary arteries.
    Cohen RA; Shepherd JT; Vanhoutte PM
    Am J Physiol; 1983 Dec; 245(6):H1077-80. PubMed ID: 6660308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenine nucleotides, serotonin, and endothelium-dependent relaxations to platelets.
    Houston DS; Shepherd JT; Vanhoutte PM
    Am J Physiol; 1985 Mar; 248(3 Pt 2):H389-95. PubMed ID: 3156512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.
    Van Nueten JM; Janssen PA; Van Beek J; Xhonneux R; Verbeuren TJ; Vanhoutte PM
    J Pharmacol Exp Ther; 1981 Jul; 218(1):217-30. PubMed ID: 6113280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet-vessel wall interactions: implication of 5-hydroxytryptamine. A review.
    De Clerck F; van Nueten JM; Reneman RS
    Agents Actions; 1984 Dec; 15(5-6):612-26. PubMed ID: 6397984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine.
    McGoon MD; Vanhoutte PM
    J Clin Invest; 1984 Sep; 74(3):828-33. PubMed ID: 6470141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous inhibition of platelet S2-serotonergic receptors during chronic administration of ketanserin in humans.
    De Clerck F; Xhonneux B
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S23-5. PubMed ID: 2412050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of platelet-derived contractile agents on human digital arteries.
    Moulds RF; Iwanov V; Medcalf RL
    Clin Sci (Lond); 1984 Apr; 66(4):443-51. PubMed ID: 6697664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of serotonin, histamine, and thromboxane A2 in platelet-induced contractions of coronary arteries and aortae from rabbits.
    Awano K; Yokoyama M; Fukuzaki H
    J Cardiovasc Pharmacol; 1989 May; 13(5):781-92. PubMed ID: 2472528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasoconstrictor expression of human platelet-vessel wall interactions: inhibition by the Ca2+ entry blocker flunarizine.
    Van Nueten JM; De Ridder W; Van Gorp L; De Clerck F
    Eur J Pharmacol; 1987 Jan; 133(3):301-8. PubMed ID: 3104067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effect of irindalone, a novel serotonin 5-HT2 antagonist and ketanserin on mechanical responses of rat thoracic aorta.
    Mikkelsen EO; Nyborg NC; Jensen KT; Boeck V
    Eur J Pharmacol; 1988 Apr; 149(1-2):145-8. PubMed ID: 3396624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effects of ketanserin, a novel serotonergic receptor antagonist, on 5HT-induced shape change and 5HT uptake in rat and human platelets.
    Lampugnani MG; de Gaetano G
    Biochem Pharmacol; 1982 Sep; 31(18):3000-2. PubMed ID: 7138588
    [No Abstract]   [Full Text] [Related]  

  • 17. 5-HT2-receptor antagonists: alpha 1- vs. 5-HT2-receptor blocking properties in blood vessels.
    Cohen ML; Schenck KW; Kurz KD
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S25-9. PubMed ID: 2459510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AHR-16303B, a novel antagonist of 5-HT2 receptors and voltage-sensitive calcium channels.
    Barrett RJ; Appell KC; Kilpatrick BF; Proakis AG; Nolan JC; Walsh DA
    J Cardiovasc Pharmacol; 1991 Jan; 17(1):41-53. PubMed ID: 1708055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation by 5-HT1A receptors of the 5-HT2 receptor-mediated tachykinin-induced contraction of the rat trachea in vitro.
    Germonpré PR; Joos GF; Pauwels RA
    Br J Pharmacol; 1998 Apr; 123(8):1571-8. PubMed ID: 9605563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arachidonate metabolism, 5-hydroxytryptamine release and aggregation in human platelets activated by palmitaldehyde acetal phosphatidic acid.
    Brammer JP; Maguire MH
    Br J Pharmacol; 1984 May; 82(1):61-72. PubMed ID: 6428500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.